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Abstract The current status of child and adolescent
psychiatric genetics appears promising in light of the ini-
tiation of genome-wide association studies (GWAS) for
diverse polygenic disorders and the molecular elucidation
of monogenic Rett syndrome, for which recent functional
studies provide hope for pharmacological treatment strat-
egies. Within the last 50 years, tremendous progress has
been made in linking genetic variation to behavioral phe-
notypes and psychiatric disorders. We summarize the
major findings of the Human Genome Project and dwell on
largely unsuccessful candidate gene and linkage studies.
GWAS for the first time offer the possibility to detect
single nucleotide polymorphisms and copy number variants
without a priori hypotheses as to their molecular etiology.
At the same time it is becoming increasingly clear that very
large sample sizes are required in order to enable genome
wide significant findings, thus necessitating further large-
scaled ascertainment schemes for the successful elucida-
tion of the molecular genetics of childhood and adolescent
psychiatric disorders. We conclude by reflecting on dif-
ferent scenarios for future research into the molecular basis
of early onset psychiatric disorders. This review represents
the introductory article of this special issue of the European
Child and Adolescent Psychiatry.
Keywords Candidate gene  Linkage  Rett syndrome 
Gene–environment interaction  Genome-wide
association study
Introduction
Over the past 50 years, substantial progress has been made
in linking specific behavioral and psychiatric phenotypes to
chromosomal aberrations or genetic variation at the DNA
level. Prerequisites of this development were significant
conceptual, methodological and technical advances in both
molecular and statistical genetics.
Advances in cytogenetics allowed the identification of
specific syndromes based on quantitative chromosomal
imbalances of complete chromosomes as in trisomy 21 in
1959 [93] and later [94] of chromosomal regions as in the
cri du chat syndrome due to monosomy 5p [94]. Approx-
imately 5 Mb represents the resolution limits of banding
techniques; fluorescent in situ hybridization (FISH) allows
detection of deletions as small as 1.5 Mb. Micro-deletions
can result in syndromes with distinct behavioral features
such as the Prader-Willi syndrome (paternal 15q11),
Angelman syndrome (maternal 15q11), and the velo-
cardiofacial/DiGeorge syndrome (22q11). Because a single
gene on average encompasses 10–15 kb, the phenotypes of
micro-deletion syndromes result from the loss of a number
of genes (partial monosomy). Quantitative imbalances can
functionally result in overexpression (e.g., trisomy or par-
tial trisomy) or underexpression (monosomy or partial
monosomy) of those genes located on a chromosome or
within a specific chromosomal region. Due to the high
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proportion of genes (&80% in mouse brain; [92])
expressed centrally, brain function is almost always per-
turbed in such disorders, thus entailing the cognitive and
behavioral phenotypes.
Findings in Down syndrome have revealed that of the
approximately 200 genes on chromosome 21 only a subset
is responsible for the characteristic phenotype. One well-
known example is the early onset of dementia in subjects
with Down syndrome, which can partially be attributed to
the over-expression of the amyloid-ß precursor protein
gene (APP) located at 21q21-22. In addition to the quan-
titative imbalance, the Down syndrome phenotype is
affected by allelic variation; for example, differences in
length of a tetranucleotide repeat in intron 7 of the APP
locus explain substantial variation in age at onset of
dementia in subjects with trisomy 21 [104].
The first large scaled and systematic genotype–pheno-
type studies with a primary behavioral, psychological and
psychiatric focus centered on sex chromosome (gonosome)
disorders; due to the low frequencies of the X0 (Turner
Syndrome), XXX (Triple X Syndrome), XXY (Klinefelter
Syndrome) and XYY syndromes thousands of newborns
had to be screened to detect low numbers of individuals
with such gonosomal disorders; the long-term follow-up of
their development into adulthood revealed that these dis-
orders are characterized by subtle neuropsychiatric and
neuropsychological symptoms such as an IQ distribution
shifted slightly to the left and elevated rates of attention
problems, speech and reading difficulties and reduced
impulse-control; nevertheless, the dissection of a highly
specific behavioral phenotype associated with any one of
these sex chromosome disorders was not possible [62].
The ability to detect variation at the DNA level formed
the basis for the successful elucidation of the molecular
mechanisms underlying many monogenic disorders, which
can entail more or less specific behavioral phenotypes
(Table 1). Most frequently, such variation is detectable in
exons of genes underlying such disorders and simplistically
either entails that the respective gene product is structurally
altered or not formed at all. For example, missense muta-
tions entail the substitution of the regular amino acid at a
specific position of the protein with another; this alteration
of the amino acid sequence of the respective protein can
have functional implications at the levels of the cell, tissue
and organism. Below, we focus on the Rett syndrome (RS),
because it is the only psychiatric disorder listed in DSM-IV
TR which in the majority of cases results from mutations in
a defined gene. Fascinatingly, within a 10-year period, the
molecular analysis of this disorder is beginning to provide
insight into potential future treatment venues and to con-
tribute to our understanding of pathways involved in per-
vasive developmental disorders, in general.
All other DSM-IV TR psychiatric disorders are most
likely complex implying that they do not at all or only
Table 1 Examples of the influence of single gene disorders on cognition and behavior
Monogenic
disorder
Mode of inheritance Gene Cognitive phenotype Behavioral phenotype Reference
Lesch–Nyhan
syndrome
X-chromosomal
recessive
Hypoxanthine guanine
phosphoribosyl
transferase (HPRT)
Mental retardation Self-mutilative biting of fingers and lips [83]
Tuberous
sclerosis
Autosomal
dominant
Tuberous sclerosis-1 and
-2 (TSC1/-2)
Learning difficulties,
low IQ, mental
retardation
Behavioral problems, autistic disorder [97]
Fragile X
syndrome
X-chromosomal,
triplet repeat
expansion
Fragile X mental
retardation (FMR1)
Mental retardation,
hyperactivity
Autism [32]
Leptin deficiency Autosomal
recessive
Leptin (LEP) Diminished perception of food reward,
decreased response to satiety signals,
hyperphagia
[39]
Chorea
Huntington
Autosomal
dominant, triplet
repeat expansion
Huntingtin (HTT) Dementia Depression, psychosis, personality
change, obsessive–compulsive
behavior
[168]
Phenylketonuria Autosomal
recessive
Phenylalanine
hydroxylase (PAH)
Mental retardation Autism [144]
Wilson’s disease Autosomal
recessive
ATPase, Cu??
transporting, beta
polypeptide (ATP7B)
Psychiatric symptoms (personality
changes, depression, psychosis)
[30]
Neurofibromatosis Autosomal
dominant
Neurofibromin (NF1) Mental retardation
hyperactivity
ADHD [3]
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infrequently result from single gene mutations. Instead, it is
assumed that several gene variants interact in a complex
manner with environmental factors to produce the pheno-
type [86]. Complex disorders typically entail higher con-
cordance rates in monozygotic than dizygotic twins;
concordance rates in monozygotic twins are typically
below 1 implying that environmental factors play a role in
the manifestation of the disorder. Family studies have
shown that complex psychiatric disorders are characterized
by elevated recurrence risks in first and second degree
relatives which are below those expected for classical
monogenic dominant or recessive traits. Moreover, for the
complex psychiatric disorders, a steep decline in recurrence
risks is observable between first and second degree family
members. In third degree relatives recurrence risks are
usually only minimally elevated above population-based
rates of the respective disorder [164].
Within child and adolescent psychiatry, the most twin,
family and adoption studies have been carried out for
attention deficit/hyperactivity disorder (ADHD; [46]).
ADHD is also noteworthy because large population-based
twin studies have analyzed quantitative dimensions of the
disorder; complex gene–environment twin studies have
also been performed. For many personality and behavioral
traits and developmental milestones heritability estimates
based on categorical or dimensional (quantitative) data
indicate that overall approximately half of the variance is
explained by genetic factors [124], the other half by the
environment (Tables 2, 3). In their seminal review, Plomin
and Daniels [125] pointed out that after controlling for
genetic similarity, siblings often appear no more alike than
individuals selected at random from the general population.
The source of this dissimilarity is a variance component
termed ‘non-shared environment’. For many traits, the non-
shared environment has been found to be of greater rele-
vance than the shared environment.
For most psychiatric disorders, which are usually assessed
categorically, genetic factors have also been shown to play
an important role (Table 4). Heritability estimates typically
exceed 0.5. ADHD has been shown to be one of the most
highly heritable child and adolescent psychiatric disorders
[18, 46, 64]. Knowledge of the magnitude of the genetic basis
of a particular disorder is valuable for interpreting psychi-
atric findings within a patient’s family and for probing for
specific disorders in relatives of the index patient.
Until recently, candidate gene and linkage studies
dominated the attempts to uncover genetic variation
underlying such complex disorders. However, viewed in
retrospect, it can be concluded that these large-scaled
efforts were largely unsuccessful; progress in the molecular
dissection of complex psychiatric phenotypes proved to be
exceedingly slow for a period of over 20 years (reviewed
in [19]). Candidate gene studies could only be performed
for those genes for which an a priori hypothesis existed as
to their relevance for the respective disorder; obviously for
each disorder this represented only a very limited number
in light of the totally known number of human genes. In
addition, candidate gene studies in different psychiatric
disorders frequently focussed on the same set of genes of a
particular neurotransmitter system, such as dopamine and
serotonin transporters and receptors (e.g., for ADHD,
obsessive compulsive disorder, and eating disorders see [9,
141, 167]). In other words, the candidate gene studies
reflected the paucity of hypotheses as to the underlying
pathways involved in complex psychiatric disorders.
Until recently, molecular genetic analyses of complex
psychiatric disorders were based on low numbers of cases
and controls or families. It has now become evident that for
many complex disorders thousands of cases and controls
are required to pick up gene variants with small effect
sizes. In 1996, Risch and Merikangas [130] had already
calculated that thousands of sib-pairs would be required to
detect linkage if the effect sizes of the relevant gene
variants are small; linkage studies only infrequently
included more than 500 sib-pairs.
In 2006, the first genome-wide association studies
(GWAS) based on DNA chip technology were introduced
(reviewed in [59]; see Table 5 for an overview of GWAS in
selected neuropsychiatric disorders), whereas it is still too
early to judge the total insight that this novel technology will
provide into the pathogenesis of complex disorders, we can
nevertheless already conclude that GWAS have entailed a
paradigm shift, thus justifying the nomination as ‘‘break-
through of the year’’ by Science magazine in 2007 [122]. For
many complex somatic and neuropsychiatric disorders,
novel genes have been detected which provide initial insights
into frequently unknown pathways involved in the respective
disorders. For many disorders, different groups pooled their
GWAS to come up with several thousand cases and controls,
such numbers had almost never been analyzed in the pre-
GWAS era. A major finding has been that the effect sizes of
validated trait or disease-related SNPs are modest to small;
according to a recent synopsis [65], the median odds ratio
was 1.33 with an interquartile range of 1.2–1.61. Despite this
recent progress, the molecular genetic basis for complex
disorders remains largely unknown. For each disorder, the
variance explained by the single newly identified gene
variants is uniformly small.
Developmental aspects represent a key feature of child
and adolescent psychiatry. The unfolding of gene expression
provides virtually all of the information necessary to guide
the orderly succession of events underlying the development
of any organism and the central nervous system, in particular
[91]. A behavioral trait or the symptoms of any given mental
disorder are more uniform for a specific developmental stage
than across all of infancy, childhood and adolescence; in
Eur Child Adolesc Psychiatry (2010) 19:259–279 261
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addition, comorbidity is dependent on developmental stage
[18]. Because developmental milestones, many traits and
disorders must be viewed in the context of brain develop-
ment, elucidation of the underlying molecular mechanisms
will contribute to the identification of genes involved in
normal development of the central nervous system and its
function. Dyslexia genes, which are involved in global brain-
development processes such as neural migration and axonal
guidance represent just one such example [106, 143]. Par-
tially heritable somatic developmental traits such as age at
menarche [158] and timing of puberty [120] have success-
fully been subjected to GWAS.
Specific disorders run their course during specific
developmental phases. Examples include enuresis nocturna
which at age 7 affects approximately 10% and at 18 only
1% [54]. The frequent reduction of hyperactivity in ADHD
during adolescence is another example. Both anorexia and
bulimia nervosa rarely start in childhood and only infre-
quently persist beyond age 30; in Tourette’s disorder, both
comorbid disorders and the development of the tics show
age-related patterns. It appears probable that alterations in
expression levels of specific genes partially account for
disorder-specific manifestation ages and the symptom
development over time (Tables 2, 3, 4).
The Human Genome Project (HGP), other relevant
international projects and interindividual variation
at the DNA level
The completion of the HGP launched in the late 1980s in
the USA [117] has provided the basis for a more rapid
discovery of novel candidate genes for complex disorders.
The first comprehensive analysis of the human draft
sequence(s) was published in February 2001 by the Inter-
national Human Genome Sequencing Consortium (IHGSC)
in Nature [78] and the private enterprise Celera Genomics
(CG) in Science [166]. Most striking was the small number
of estimated human genes, which had previously been
thought to range up to over 100,000. Also, it became
apparent that only *1.5% of the human genome contains
coding information. About *50% is composed of repeti-
tive elements. Hence, human complexity is based on
diversity and finely tuned interaction of gene products such
as RNA and proteins rather than gene numbers. Consistent
with this, *50% of human protein coding genes exhibit
alternative splicing [13, 111, 112] creating a proteome of
[90,000 proteins [60]. Gene expression is regulated by the
complex interaction of a wide variety of transcription
factors [43, 151].
In April 2003, in the 50th anniversary year of the dis-
covery of the double-helical structure of DNA [171], the
human DNA sequence was virtually completely elucidated.
It represented *99% of the euchromatic portion of the
human genome (2.85 Gb) with 99,999% accuracy [79]. Of
main interest is the identification of all genes and a com-
prehensive genome annotation. Currently, 31,315 genes
(including 9,899 pseudogenes, which are not transcribed)
are listed in the human gene catalogue (Ensemble Database
version 54.36p). The total number of protein coding genes
is estimated at 20,000–25,000, which is consistent with
data from cross species comparisons [115, 132]. The fin-
ished sequence also provides the basis for the identification
of potentially all genes causing or predisposing to disease
Table 2 Selected heritability estimates of personality dimensions
Assessments Heritability estimates Reference
Female (%) Male (%)
Extraversion EPQ-R 57 57 [85]
Neuroticism EPQ-R 54 49 [85]
Lie EPQ-R 44 35 [85]
Psychoticism EPQ-R 39 43 [85]
Harm Avoidance TCI 53 57 [85]
Novelty Seeking TCI 55 55 [85]
Reward depending TCI 56 51 [85]
Persistence TCI 55 55 [85]
The ‘‘Big Five’’
Extraversion NEO-PI-R 53 [82]
Neuroticism NEO-PI-R 41 [82]
Openness NEO-PI-R 61 [82]
Agreeableness NEO-PI-R 41 [82]
Conscientiousness NEO-PI-R 44 [82]
EPQ-R Eysenck Personality Questionaire [37], TCI Temperament and Character Inventory [26], NEO-PI-R NEO Personality Inventory [29]
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as well as genetic variations affecting individual responses
to medication and environmental factors. To detect varia-
tion in a DNA region of interest (e.g., a gene repeatedly or
unambiguously identified in GWAS) in individuals with a
specific disorder, the respective regions are commonly re-
sequenced.
Interspecies comparison is helpful to identify regulatory
regions and functional motifs, and so sequencing of many
prokaryotic as well as eukaryotic organisms including
mammals (mouse, rat, cat, chimpanzee, cow and dog) is
completed or well under way. Comparison of highly
accurate genome sequences enables the study of genome
evolution, i.e., lineage-specific gene birth [35, 116, 121,
135]. Chimpanzee is the closest relative to humans having
DNA sequences 98% identical to each other. Of special
medical interest is the high proportion of recent segmental
duplications [7] and inversions [42] in the human genome.
The respective chromosomal regions are prone to rear-
rangements and/or deletions potentially resulting in phe-
notypic effects and can now be reliably analyzed [24, 108].
To systematically identify all genetic variations in the
human population, the international HapMap Project was
initiated in 2002 [77]. Populations with African, Asian, and
European ancestry are studied to identify and catalogue
genetic similarities and differences in humans. Genotyping
a subset of these in the three populations generates an
invaluable resource for the discovery of genes related to
complex disorders via GWAS.
The Human Epigenome Project [74] aims to identify,
catalogue and study genome-wide DNA methylation pat-
terns. DNA methylation is a natural modification of the
nucleotide cytosine via which gene expression is con-
trolled. It is tissue-specific and changes over time in
response to environmental factors. DNA methylation thus
represents a direct link between environment and an indi-
vidual’s state. Epigenetic differences between monozygous
twins potentially account for phenotypical variation despite
an identical genome at the DNA level. Although twins
have been found to be epigenetically indistinguishable
during the early years of life, older monozygous twins
exhibited remarkable differences in their overall content
and genomic distribution of 5-methylcytosine DNA and
histone acetylation, affecting their gene-expression portrait
[45]. These findings indicate how an appreciation of epi-
genetics is currently largely missing from our understand-
ing of the origin of different phenotypes from the same
genotype.
The international Human Brain Proteome Organization
Project (HBPP) is concerned with the brain proteome in
health, aging and neuropsychiatric disorders [109]. The
Encyclopedia of DNA Elements Project (ENCODE) aims
at identifying all functional elements in the human genome
[36]. Together with these and future initiatives, the HGP
Table 4 Heritability estimates of selected psychiatric disorders
Disorder Heritability estimates (%) Reference
PDD 90 [139]
Enuresis 67–70 [54]
Conduct disorder 53 [51]
OCD 47 [25]
Anxiety disorders 30–40 [33]
ADHD 60–80 [64]
Anorexia nervosa 48–88 [141]
Bulimia nervosa 28–83 [141]
Schizophrenia 73–90 [160]
Bipolar disorder 60–85 [149]
Major depression 31–42 [159]
OCD Obsessive Compulsive Disorder; PDD Pervasive Develop-
mental Disorders (including autistic disorder, Asperger disorder,
disintegrative disorder, and PDD not otherwise specified); ADHD
Attention Deficit/Hyperactivity Disorder
Table 3 Heritability estimates of selected behaviors and develop-
mental milestones
Assessments Heritability
estimates (%)
Reference
Behaviors
Dieting EAT 42 [134]
Body
dissatisfaction
EDI 52 [134]
Drive for thinness EDI 44 [134]
Disinhibition of
eating
TFEQ 40 [155]
Restrained eating TFEQ 28 [155]
Hunger TFEQ 28 [155]
Obsessive
compulsive
behav.
CBCL 45–58 [71]
Developmental milestones
Motor
development
Crawling, sitting
standing, walking
90 [53]
Crawling, sitting,
walking
22–33 [123]
Standing 0 [123]
Heritability
estimates (%)
Female Male
Expressive
language
‘‘vocabulary’’
MCD-I-R 8 20 [73]
‘‘Two-word-
combination-use’’
MCD-I-R 28 10 [73]
EAT Eating Attitudes Test [49], EDI Eating Disorder Inventory [50],
MCD-I-R MacArthur Communicative Development Inventories-short
form [40], CBCL Child Behavior Checklist [2], TFEQ Three Factor
Eating Questionnaire [157]
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Table 5 Examples of single nucleotide polymorphisms (SNPs) and copy number variations (CNVs) detected in genome wide association studies
(GWAS) for selected neuropsychiatric disorders
Disorder Gene(s) or region Marker-risk allele P value Sample (cases/controls) Reference
Restless legs syndrome
GWAS PTPRD rs4626664-A 6 9 10-10 628/1,644; replication in 1,835/3,111 [142]
rs1975197-T 6 9 10-9
BTBD9 rs3923809-A 3 9 10-14 306/15,633; replication in 311/1,895 [152]
MEIS1 rs2300478-G 3 9 10-28 401/1,644; replication in 1,158/1,178 [176]
BTBD9 rs9296249-T 4 9 10-18
MAP2K5, LBXCOR1 rs12593813-G 1 9 10-15
ADHD
CNV CTNND2, GRM5, GRM7, PARK2 Deletions 9.48 9 10-3 335 parent–child trios/2,026 [34]
Schizophrenia
GWAS ZNF804A rs3923809-A 1.61 9 10-7 479/2,937; replication in 6,666/
19,897
[118]
CSF2RA, IL3RA rs4129148-C 4 9 10-7 178/144 [95]
MHC/HIST1H2BJ rs6913660-C 1.1 9 10-9 2,663/13,498; follow-up in 4,999/
15,555
[154]
MHC/PRSS16 rs13219354-T 1.3 9 10-10
rs6932590-T 1.4 9 10-12
MHC/PGBD1 rs13211507-T 8.3 9 10-11
MHC/NOTCH4 rs3131296-G 2.3 9 10-10
NRGN rs12807809-T 2.4 9 10-9
TCF4 rs9960767-C 4.11 9 10-9
MHC class 1 region rs13194053-C 9.5 9 10-9 3,322/3,587; meta-analysis with
8,008/19,077
[80]
6p22.1 9.54 9 10-9 Meta-analysis of 8,008/19,077 [147]
CNV 1q21.1 2.9 9 10-5 1,433/33,250; replication in 3,285/
7,951
[153]
15q11.2 6 9 10-4
15q13.3 5.3 9 10-4
Bipolar disorder
GWAS ANK3 rs10994336-T 9 9 10-9 4,387/6,209 [41]
CACNA1C rs1006737-A 7 9 10-8
DGKH rs1012053-A 2 9 10-8 461/563 [10]
PALB2, NDUFAB1, DCTN5 rs420259-A 6 9 10-8 1,868/2,938 [173]
Autism
GWAS CDH10, CDH9 rs4307059-T 2 9 10-10 1,204/6,491; 3,101 family members;
replication in 1,390 family
members;
108/540
[170]
CNV MDGA2 Exonic deletions 1.3 9 10-4 912 families/1,488; replication in
859/1051
[17]
BZRAP1 Exonic deletions and duplications 2.3 9 10-5
AK123120 Duplication 3.57 9 10-6 859/1,409; replication in 1,336/
1,110 cc1
[52]
PARK2, UBE3A, RFWD2, FBXO40 Duplication or deletion 3.3 9 10-3
NLGN1, ASTN2 Duplication or deletion 9.5 9 10-3
16p11.2 Microdeletions/microduplications 751 families/4,234; replication in
811/19,268
[172]
PTPRD protein tyrosine phosphatase, receptor type, D; BTBD9 BTB (POZ) domain containing 9; MEIS1 Meis homeobox 1; MAP2K5 mitogen-activated
protein kinase kinase 5; LBXCOR1 LBXCOR1 homolog; CTNND2 catenin delta-2; GRM5 glutamate receptor metabotropic 5; GRM7 glutamate receptor
metabotropic 7; ZNF804A zinc finger protein 804A; RELN reelin; CSF2RA colony stimulating factor, receptor 2 alpha; IL3RA interleukin-3 receptor
subunit alpha; MHC major histocompatibility complex; HIST1H2BJ histone cluster 1 H2bj; PRSS16 thymus-specific serine protease; HIST1H2BJ histone
H2B type 1-J; PGBD1 PiggyBac transposable element-derived protein 1; NOTCH4 notch homolog 4; NRGN neurogranin; NLGN1 neuroligin 1; TCF4
neurogranin, transcription factor 4; ANK3 ankyrin 3; CACNA1C calcium channel, voltage-dependent, L type, alpha 1C subunit; DGKH diacylglycerol
kinase eta; PALB2 partner and localizer of BRCA2; NDUFAB1 NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1; DCTN5 dynactin subunit
5; CDH10 Cadherin-10 precursor; CDH9 cadherin-9 precursor; MDGA2 MAM domain containing glycosylphosphatiddylinositol anchor 2; BZRAP1
benzodiazapine receptor (peripheral) associated protein 1; AK123120 cDNA; PARK2 Parkinson disease 2; RFWD2 ring finger and WD repeat domain 2;
UBE3A ubiquitin-protein ligase E3A; FBXO40 F-box protein 40; ASTN2 astrotactin 2
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demonstrates the immense power lying in coordinated
efforts to provide the foundation of biological and bio-
medical research at a new, more global but at the same time
intertwined level. More recently, the 1,000 Genomes Pro-
ject was initiated to re-sequence the genomes of at least
1,000 individuals from around the world to create the most
detailed and medically useful picture to date of human
genetic variation [162].
The comparison of whole genome sequences between
individuals has allowed the detection of substantially more
variation than expected [96, 169]. It had been assumed that
most variation is due to single nucleotide polymorphisms
(SNPs; exchanges at the level of a single base). Any two
individuals differ by only one in 1,000 DNA bases or at
approximately 3 million bases out of the total of 3 billion
in the human genome. However, the comparison of a single
sequenced genome (that of Craig Venter) with the National
Center for Biotechnology Information human reference
assembly identified more than 4 million variants (almost
1.3 million were novel) encompassing more than 12 Mb;
roughly 1 million variants were not due to SNPs; instead
these variants encompassed block substitutions, insertion/
deletion events (indels), 90 inversions, as well as numerous
segmental duplications and copy number variation (CNV)
regions. In total, non-SNP DNA variation accounted for
22% of all events identified in the genome of Craig Venter,
which however accounted for 74% of all variant bases,
suggesting an important role for non-SNP genetic altera-
tions in defining the diploid genome structure [96]. 44% of
Venter’s genes were heterozygous for one or more variants.
Due to their importance in neuropsychiatric genetics
[28], CNVs deserve particular notice. These are defined as
segments of DNA as large as several megabases in which
copy number differences due to genomic rearrangements
such as inversions, deletions, duplications and transloca-
tions have been found via representational oligonucleotide
microarray analysis [145] and comparison of genomes
(e.g., [88, 96]); CNVs are either inherited or de novo. It is
estimated that approximately 0.4% of the genomes of
unrelated people typically differ with respect to copy
number [88].
RS as a monogenic psychiatric disorder
Originally, Rett [128] delineated the features of this serious
neuropsychiatric disorder in three females; 17 years later,
Hagberg et al. [58] reported on 35 females with ‘progres-
sive autism, loss of purposeful hand movements, ataxia,
and acquired microcephaly’, which represent the cardinal
symptoms of the disorder with an incidence of approxi-
mately 1 out of 10,000 female live births. After apparently
normal development for 6–18 months, girls with RS lose
acquired cognitive, social, and motor skills and develop
autistic behavior accompanied by stereotypic hand move-
ments. As the disorder progresses severe mental retardation
and motor impairments, including ataxia, apraxia, and
tremors ensue. Seizures, hyperventilation, apnea and
feeding difficulties are also common. The disorder is spo-
radic in 99% of all cases [22]. The RS brain is small for age
and height of the patient. Dendritic trees in pyramidal
neurons of layers III and V in selected lobes are small. The
RS brain has small neurons with an increased neuronal
packing density; it exhibits a changing pattern of neuro-
transmitter receptors with an apparent reduction in many
neurotransmitters [5].
In 1999, different mutations in the methyl-CpG binding
protein 2 gene (MECP2; human genes are commonly
abbreviated in italic capital letters) were detected in RS
females [4]. This discovery marked a turning point in
psychiatric genetics: a DSM-IV (and ICD-10) psychiatric
disorder was found to be due to mutations within a single
gene. About 95% of classical RS patients have one of[300
known pathogenic MECP2 mutations, the spectrum of
which includes missense, nonsense, and frameshift muta-
tions and deletions [22], the last three entailing a more
severe phenotype. The X-chromosomal location (Xq28) of
MECP2 explains why mostly only females are affected:
males, who have only one copy of MECP2, are frequently
not viable, if the gene is mutated. In those alive at birth, a
much more severe clinical phenotype results; death mostly
occurs prior to age 2.
Seemingly, both a reduced and an elevated expression of
MECP2 lead to a similar phenotype: duplications of Xq28
including MECP2 were detected in males with clinical
features similar to RS. Transgenic mice that express wild-
type Mecp2 (only the first letter of murine genes is capi-
talized) at twice the normal level also have a progressive
neurological phenotype similar to that observed in human
patients [27].
MECP2 and the RS phenotype
MECP2 is expressed in all tissues. In the adult mouse,
Mecp2 (protein encoded by Mecp2) is high in brain, lung
and spleen, lower in heart and kidney, and barely detect-
able in liver, stomach and small intestine. The timing of the
expression of murine Mecp2 and human MECP2 in humans
has been shown to correlate with the maturation of the
central nervous system, with the ontogenetically older
structures such as the spinal cord and brainstem becoming
positive before newer structures such as the hippocampus
and cerebral cortex. In the cortex, MeCP2 first appears in
the Cajal-Retzius cells, then in the neurons of the deeper,
more mature cortical layers, and finally in the neurons of
the more superficial layers [146]. Both timing and
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localization of MECP2 expression should explain devel-
opmental aspects of the RS phenotype.
MECP2 is subject to alternative splicing (different
processing of the mRNA results in proteins of different
sizes with partially identical domains). The B isoform has
the highest expression in brain, and mutations specific
to the exons encoding this isoform are sufficient to cause
RS. The respective protein MeCP2 includes four functional
domains, one of which is the methyl-CpG binding domain
(MBD). This protein domain binds to symmetrically
methylated CpGs located in the upstream region of many
genes; binding of MeCP2 to methylated CpGs has an
influence on the transcription rate of such a gene and is thus
an important epigenetic mechanism in the regulation
of distinct genes. The three other functional domains
include an arginine-glycine repeat RNA-binding domain, a
transcriptional repression domain that interacts with a
co-repressor complex involving mSin3A and histone
deacetylases and a RNA splicing factor binding region [165].
MeCP2 seemingly influences the transcription of a
limited number of specific genes as either a repressor or
activator, which is not only due to MeCP2 binding to CpG-
islands but also to periodic MeCP2 binding outside gene
boundaries, entailing the organization of chromatin into
functionally important domains or loops of imprinted
regions [70, 178], which, in turn, modulate gene expres-
sion. If due to a non-functional (or over-expression of)
MeCP2, the expression of target genes continues or is not
initiated, more and more RS symptoms ensue over time
[11]. Future research will potentially reveal which RS
symptoms are related to activation or repression of specific
genes due to the loss of function of MeCP2. For example,
the frequent feeding problems in RS might be related to the
persistent expression of brain-derived neurotrophic factor
(BDNF), which aside from being involved in the regulation
of neural survival, development, function, and plasticity in
the brain also has an influence on feeding behavior and
body weight regulation [61].
Transgenic and knockout mice models and comparative
sequence analysis [127] have helped considerably to elu-
cidate the function of MeCP2, to assess the effect of spe-
cific mutations on the phenotype and to enable the
identification of evolutionary conserved regions. If Mecp2
is completely knocked out in male mice, a mild RS-like
phenotype ensues (female mice remain healthy into
adulthood). A conditional knockout of Mecp2 in postnatal
neurons of restricted regions in the brain leads to a similar
although delayed neuronal phenotype, suggesting that the
gene plays a role in post-mitotic neurons. Abnormalities in
social interaction and home-cage behavior were identified
in mice, in which a mutation similar to common RS
causing alleles had been introduced [113]. The resultant
phenotype was reminiscent of the sleep/wake dysfunction
and autistic features of RS patients. Interestingly, trans-
genic expression of Mecp2 in Mecp2 knockout mice lar-
gely rescues the RS phenotype [101].
Although it is thought that the primary cause of RS
results from a lack of functional MeCP2 in neurons (cell
autonomous), non-cell autonomous factors also contribute
to the disease. Thus, loss of MeCP2 also occurs in glial
cells of RS brains [8, 102]. Because mutant astrocytes from
a RS mouse model, and their conditioned medium, failed to
support normal dendritic morphology of either wild-type or
mutant hippocampal neurons, astrocytes in the RS brain
carrying MECP2 mutations may have a non-cell autono-
mous effect on neuronal properties, probably as a result of
aberrant secretion of a soluble factor(s) [8].
MeCP2 deficiency in astrocytes causes significant
abnormalities in BDNF regulation, cytokine production,
and neuronal dendritic induction, which may contribute to
abnormal neurodevelopment. In addition, the MeCP2
deficiency state can progressively spread at least in part via
gap junction communications between mosaic Mecp2-/?
astrocytes in a novel non-cell-autonomous mechanism,
which may lead to the pronounced loss of MeCP2 observed
selectively in astrocytes in mouse Mecp2-/? brain, which
is coincident with phenotypic regression characteristic of
RS. Based on these findings, Maezawa et al. [102] suggest
that astrocytes are viable therapeutic targets for RS and
perhaps regressive forms of autism.
A broader role of MECP2 in neurodevelopmental
disorders
Significant differences in MeCP2 expression have been
detected between brain samples of individuals with related
neurodevelopmental disorders, including autism, pervasive
developmental disorder, Prader-Willi and Angelman syn-
dromes and age-matched controls [136, 137]. Hence, the
elucidation of the molecular mechanisms underlying RS
has led to the theory that multiple pathways regulate the
complex developmental expression of MECP2 and are not
only defective in RS but also in other autism spectrum
disorders. The common features of human neuro-develop-
mental disorders caused by loss or increase of MeCP2
function suggest that even modest alterations of MeCP2
levels result in neurodevelopmental problems. In support of
this hypothesis, a 50% reduction of the level of wild-type
MeCP2 in mice was shown to result in a spectrum of subtle
abnormalities such as learning and motor deficits,
decreased anxiety, altered social behavior and nest build-
ing, decreased pain recognition and disrupted breathing
patterns [138]. Seemingly, the precise control of MeCP2
expression level is critical for normal behavior.
A series of studies have aimed at assessing the role of
MECP2 and related genes in autistic disorder and mental
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retardation. MECP2, MBD1, MBD2, MBD3, and MBD4
comprise a nuclear protein family sharing the methyl-CpG
binding domain (MBD) and are related to transcriptional
repression. However, mutations in MECP2 have only
infrequently been detected in patients with autistic features;
mutations in the other genes have not systematically been
found to play a role in the etiology of autistic disorders
[98]. Future candidate gene studies in autism spectrum
disorders can focus on those genes whose expression levels
are regulated by MeCP2 (see, e.g., [165]). The investiga-
tion of the role of frequent MECP2 polymorphisms in
polygenic autism also merits consideration: in two family
samples a three-marker SNP haplotype was associated with
autism and autism spectrum disorders suggesting that one
or more functional variants of MECP2 existing at signifi-
cant frequencies in the population may confer increased
risk [100].
Therapeutic implications
The finding that transgenic expression of Mecp2 in Mecp2
knockout mice largely rescues the RS phenotype [101]
suggests that RS might be amenable to treatment. Because
treatment would typically only be possible after the diag-
nosis of RS and thus after development of clinical symp-
toms, this rescue in the mouse model appears promising for
the treatment of RS patients. As systemic treatment of
MeCP2 mutant mice with an active peptide fragment of
Insulin-like Growth Factor 1 (IGF-1) extends life span,
improves locomotor function, ameliorates breathing pat-
terns, and reduces irregularity in heart rate IGF-1 has been
suggested as a prime candidate for pharmacological treat-
ment of RS and other disorders caused by a deficit in
synapse maturation in the brain [163]. Treatment with IGF-
1 peptide was also shown to increase brain weight of the
mutant mice; additionally, IGF-1 partially restored spine
density and stabilized cortical plasticity to wild-type levels
[163]. In Mecp2 mutants, BDNF overexpression extended
the lifespan, rescued a locomotor defect, and reversed an
electrophysiological deficit [23].
Histone deacetylases (HDACs) are enzymes that affect
the acetylation status of histones and other cellular pro-
teins. Pharmacological manipulations using small-mole-
cule HDAC inhibitors, which may restore transcriptional
balance to neurons, modulate cytoskeletal function, affect
immune responses and enhance protein degradation path-
ways, have proven beneficial in various experimental
models of brain diseases [84] and could thus prove bene-
ficial in diverse neurodevelopmental disorders including
RS. In other genetic disorders, it has been shown that
aminoglycosides can cause a read-through of nonsense
mutations with an efficiency of up to 20%. Brendel et al.
[12] showed that this read-through of MECP2 nonsense
mutations can be achieved in vitro with efficiency com-
parable to that seen in other disorders.
Identification of predisposing alleles
in complex disorders
In conclusion, within a ten year period, substantial progress
has been made in elucidating the molecular mechanisms
underlying RS and deducing strategies for potential treat-
ment. The situation in polygenic disorders is obviously
much more complex. In the following, we examine how
gene variation can be picked up in complex disorders.
Association studies
The comparison of genetic variants between cases and
controls is the most common approach taken to identify
variants predisposing to the respective disorder. In associ-
ation studies, a familial loading is per se not required for
classification as a case. However, requirement of such a
loading would be expected to increase the probability that
genetic factors indeed contribute to the disorder of the
index patient. Controls are frequently screened for the
respective disorder; a positive screen entails exclusion of
the proband as a control. Use of controls with a phenotype
that quantitatively differs as much as possible from cases
can theoretically enhance the probability of detecting
genes. Controls should be matched to cases for well-
established, strong risk factors (e.g., ethnic group, sex,
socio-economic status and intelligence) to ensure that sig-
nificant results are not caused by a confounding risk factor
differing between the two groups other than the trait of
interest [89]. Such confounders would bias the study if they
interact with the considered candidate gene. Overmatching,
on the other hand, e.g., for many potential, small risk
factors, will lead to substantial loss of efficiency. Matching
has to be accounted for in the analysis as well.
One of the most important confounders in genetic
studies could be ethnicity in ethnically admixed or struc-
tured populations [90]. This will cause serious bias if the
studied candidate gene differs in allele frequencies between
ethnically defined sub-populations (population stratifica-
tion). It has been proposed to genotype several markers that
are thought to bear no relationship to the disorder of
interest in both cases and controls to potentially enable
adjustment for systematic genetic differences [31, 126];
this has become a standard requirement for GWAS (see
below, [6]).
Another popular approach to circumvent the potential
confounding population stratification effects of case–con-
trol studies are family-based association studies, which
include family members of the cases to use as (ethnically)
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matched controls. These can be unaffected sibs or pseudo-
controls constructed from non-transmitted parental alleles.
The first statistical tests for such case-parent trios were the
haplotype relative risk method (HRR; [38]) and the hap-
lotype-based haplotype relative risk method (HHRR;
[161]). These tests influenced the development of the most
widespread test—the transmission disequilibrium test
(TDT; [150]) which is unaffected by population stratifica-
tion phenomena and a valid test for both association and
linkage. The TDT test statistic is based on the comparison
of the number of times the allele of interest is transmitted
versus non-transmitted by heterozygous parents to an
affected child. The ascertainment of parents is usually
readily possible in disorders with a childhood onset.
Family-based association studies have certain disad-
vantages; in particular, they are less efficient than case–
control studies. Sibs share on average one allele identical
by descent, so there is effectively only one allele that can
differ instead of two for unrelated cases and controls. Also,
sibs tend to be more similar in many possible risk factors
which imply over-matching with its associated loss in
efficiency. In the trio design, three subjects have to be
genotyped to yield approximately the similar information
as two subjects in the case–control design. And finally, for
diseases with a later age-of-onset, it will be difficult to
ascertain parents of cases. Therefore, family-based
association studies are more expensive and complex than
case–control studies.
Effect size
In polygenic disorders, each gene variant (subsequently
also referred to as an allele) has only a minor to minimal
effect. Typically the effect size of a particular allele or
genotype is indicated via its relative risk or the odds ratio
in case–control designs. In diploid cells, humans have two
copies of every gene (with the exception of most genes
located on the X and Y chromosomes in males); in this
context, the term genotype refers to both gene variants;
typically the genotype relative risk is given for heterozy-
gotes (AB) and homozygotes (BB) for the predisposing
allele, it is set to 1 in individuals homozygous for the wild-
type allele (AA). Low relative risks imply that (1) the
variant (or genotype) in itself is by no means sufficient to
explain the disorder of an affected individual and (2) many
individuals without the respective disorder harbor the same
allele (or genotype).
Given a limited number of cases and controls (e.g.,
1,000 each), detection of predisposing alleles becomes
more difficult (a) the lower the population frequency of
such a variant and (b) the lower its effect size. A study is
underpowered if a significant difference cannot reliably be
detected between cases and controls. Recent GWAS for
height, weight and body mass index (BMI in kg/m2) based
on ten thousands of individuals have picked up single
variants which in the heterozygous state on average entail a
3 mm increased height [57] and a 180 g heavier weight
[175], respectively. Because presumably only those gene
variants with the most pronounced effects have currently
been detected, effect sizes of most as yet undetected alleles
may well be below 2 mm or 100 g. The implications for
psychiatric disorders are evident: whereas previous
molecular genetic studies frequently at best included only a
few hundred individuals, current studies already include
thousands of cases and controls. Many more are needed to
confirm initial true positive or to rule out false negative
findings in independent samples.
Common variants versus private mutations
The common disease—common variant hypothesis pre-
dicts that specific common alleles or variants predispose
to common disorders and that such alleles/variants will be
found in all human populations, in which the respective
disease occurs. Indeed, for several complex traits and
disorders common variants, mostly SNPs, have been
detected in coding and regulatory sequences of genes
(e.g., [65, 76]); however, in many cases the localization of
such a SNP does not allow any conclusions as to how this
variation affects the function of the gene; it appears likely
that in many cases, the respective SNP in itself merely
tags a functionally relevant SNP or variant (linkage dis-
equilibrium) in close proximity. In addition, because such
SNPs can be located far from a gene it frequently is not
even possible to definitely determine which gene (e.g., 30
or 50) is altered in its function. It appears likely that many
of the functional variants influence gene expression
levels.
The identification of variants with moderate effect sizes
has been successful in single non-psychiatric disorders with
complex inheritance such as Crohn’s disease [72, 119],
breast cancer [110, 177], and type 2 diabetes mellitus [56].
However, for complex psychiatric disorders, common gene
variants with modest and robust effect sizes have not been
detected. Even upon use of large-scaled GWAS (see
below), the total number of validated common variants is
rather low and their effect sizes are uniformly small.
Despite the recent advances, the explained variance of a
quantitative phenotype remains low even if heritability
estimates are high. Thus, even though heritability estimates
exceed 0.8 for body height, less than 5% of the total var-
iation in height has been uncovered despite the detection of
over 40 validated gene variants [57, 69]. Similarly, only
about 1% of the variance in BMI has currently been found
to be due to about 20 common variants [67, 68, 175]
despite heritability estimates of roughly 0.4–0.8.
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The common disease—common variant hypothesis has
been challenged. Based on molecular genetic findings, a
recent discussion has focused on the relevance of ‘‘private’’
mutations defined as rare mutations found only in single
families in whom a specific complex disorder occurs.
Particularly for disorders with reduced fecundity, associ-
ated with severe mental disorders, a negative selection
pressure conceivably acts on risk alleles, thus potentially
explaining why common variants have not been readily
detected in disorders such as autism, schizophrenia and
mental retardation. Accordingly, rare variants may account
for a larger fraction of the overall genetic risk than previ-
ously assumed. Indeed, rare CNVs have been detected in
schizophrenia [153], autism (reviewed in [47]) and mental
retardation [107]. For example, Stefansson et al. in a
genome-wide search for CNVs associating with schizo-
phrenia used a population-based sample to identify de novo
CNVs by analyzing 9,878 transmissions from parents to
offspring. The 66 de novo CNVs identified were tested for
association in a sample of 1,433 schizophrenia cases and
33,250 controls. Three deletions at chromosomes 1q21.1,
15q11.2 and 15q13.3 showing a nominally significant
association with schizophrenia in the first sample were
followed up in a second sample of 3,285 cases and 7,951
controls. All three deletions were significantly associated
with schizophrenia and related psychoses in the combined
sample.
In complex disorders, different sets of gene variants are
operative in different affected individuals. Assume that 100
genes each occurring as the two alleles A and B in the
population in total account for all genes predisposing to a
particular disorder; all of these variants would have the
same effect size and would act in an additive manner. Let
us also assume that at least 50 predisposing alleles must be
present in an individual for the disorder to break out, if
predisposing environmental factors are abundant—more
predisposing alleles would be necessary if only a limited
number of negative environmental factors are operative.
Accordingly, an affected subject could theoretically be
homozygous for the predisposing variant at 25 loci, another
could be heterozygous at 50 loci. Most affected individuals
would be heterozygous at some loci and homozygous at
others. Clearly in this scenario, any two affected individ-
uals would not necessarily share a single predisposing
variant; there is substantial genetic heterogeneity.
In reality, the frequencies and effect sizes of such alleles
differ. Despite the fact that for the two quantitative phe-
notypes height and BMI effect sizes of currently detected
variants have been shown to be additive, non-additive
effects appear likely in complex disorders. Also consider
that complex interactions of specific sets of gene variants
presumably occur with environmental factors. Thus, a
particular (set of) environmental factor(s) might only be
relevant for a subgroup of individuals characterized by
specific genotypes at diverse loci. Yet in current studies, all
the individuals of such subgroups are analyzed as if they
were a homogeneous sample.
We briefly dwell on the different strategies to detect
gene variants in complex disorders.
Candidate gene studies
For many years, the candidate gene approach formed the
most frequent attempt to discover genetic variation
underlying psychiatric disorders. The choice of a specific
candidate gene was commonly based on pharmacological,
physiological, biochemical, anatomical and/or genetic data
such as chromosomal localization within a linkage region
or chromosomal breakpoints in chromosome aberrations in
individuals with a psychiatric phenotype. However, in light
of the estimated 21,000 human genes and our poor
knowledge of the molecular basis of any psychiatric dis-
order, the a priori probability for the involvement of a
particular gene is low, unless the underlying hypothesis is
well founded. Most of the respective genes were originally
selected because they belong to neurotransmitter systems
assumed to be involved in psychiatric disorders (e.g.,
dopaminergic or serotonergic system). Typically, originally
positive findings were not unequivocally confirmed in
subsequent independent association studies; meta-analyses
have been used to assess such conflicting findings. While
meta-analyses may be useful to circumvent the problem of
limited statistical power due to small samples, they are no
means to cope with poor study quality (e.g., [99]). The
advent of GWAS has led to an almost complete halt of
classical candidate gene studies; in retrospect, their con-
tribution to the elucidation of genetic mechanisms in psy-
chiatric disorders has been minimal. Because, as has been
pointed out, case numbers were frequently low, it remains
to be seen if some classical candidate genes for diverse
psychiatric disorders will be picked up in large GWAS.
To illustrate the candidate gene approach we refer to a
study conducted by Abelson et al. [1], who identified a
patient presenting with Tourette’s disorder (TD) and
ADHD carrying a de novo chromosome 13 inversion.
Because the Slit and Trk-like family member 1 gene
(SLITRK1) is one of three genes located within 500 kb of
the two breakpoints, this gene was considered as a candi-
date gene for TD. Accordingly, SLITRK1 was screened in
174 patients with TD. One subject with TD and ADHD
harbored a frameshift mutation; two unrelated patients with
TD and obsessive–compulsive symptoms had an identical
non-coding variant. Both this variant and the frameshift
mutation were absent in 4,926 and 3,600 control chromo-
somes, respectively. Abelson et al. concluded that SLIT-
RK1 mutations underlie TD in a small subgroup of patients
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affected with this tic disorder. However, caution is war-
ranted because in contrast to the 174 TD patients, SLITRK1
was not screened for mutations in controls; hence, it cannot
be excluded that healthy controls might also harbor other
infrequent mutations.
Genome-wide linkage studies
DNA sequences at specific loci are inherited together as a
consequence of their physical proximity on a single chro-
mosome. The closer the loci are to each other at the DNA
level, the lower the probability that they will be separated
during meiosis, and hence the greater the probability that
they will be inherited together. By analyzing genetic mei-
otic recombination frequencies between specific loci,
genetic linkage analysis can be used to localize suscepti-
bility genes within a framework map of genetic markers
with known positions in the genome. Genome scans have
typically been based on 350–1,000 microsatellite markers
spaced rather evenly throughout the genome with marker
distances of about 10–3 cM [114]. Fine mapping with
additional markers is frequently performed in an attempt to
narrow in the chromosomal region which initially can span
over a large region of a chromosome encompassing several
genes. A priori hypotheses as to functional candidate genes
that could influence the phenotype are not required. In
addition, no a priori assumptions about mode of inheri-
tance, frequency of the disease allele in the general popu-
lation and penetrance are required; such analyses are also
termed non-parametric or model-free. For parametric
linkage analyses, the search space is usually restricted to
for instance specific modes of inheritance; thus, a priori
assumptions are made.
Linkage studies proved to be very successful for
monogenic Mendelian disorders; nevertheless, progress
usually was slow: for example, it took from 1983 to 1993 to
proceed from the initial linkage finding on chromosome 4p
in large pedigrees to the identification of the Huntingtin
gene and the molecular mechanism underlying Hunting-
ton’s disease [75]. In complex disorders, linkage studies
were originally also based on large, multiply affected
pedigrees based on the (potentially incorrect) assumption
that a single or only a small number of disease genes
segregate in each of these families. Sibling pairs and small
nuclear families formed the basis of more recent linkage
studies [129].
With single exceptions (e.g., see [143], for linkage
findings in dyslexia leading to the detection of doublecortin
domain containing 2 gene) linkage scans for psychiatric
disorders have failed. Potential explanations include: (1)
sample sizes typically ranged well below 500 sib-pairs and
thus had (very) low power. Meta-analyses of linkage
studies have been performed in an attempt to cope with the
small number of sib-pairs investigated in single studies; for
example, for ADHD a genome-wide significant linkage
was detected on chromosome 16 [179], in contrast no
significant linkage finding was detected for obesity [140].
(2) If infrequent/rare gene variants (private mutations) with
large effect sizes (major genes) exist in psychiatric disor-
ders, their detection via linkage studies is exceedingly
difficult or impossible. It remains to be seen to what extent
GWAS will pick up genes located within linkage peaks
detected via previous linkage studies; we are aware of one
such example [140].
Genome-wide association studies (GWAS)
The possibility to place hundreds of thousand oliogonu-
cleotides on small chips in combination with the advances
of the Human Genome and related projects has revolu-
tionized molecular genetic studies of complex traits and
disorders. This transition to SNP-based technology has
been rendered possible by the construction of a map of
naturally occurring polymorphisms [81]: 1.4 million
unique SNPs were built in a *2-kb-resolution map placing
*2–4 SNPs per human gene. Currently, there are
*79 million submitted, 18 million referenced and
6.6 million validated SNPs known (latest update: 30 April
2009 [148]). Furthermore, the construction of a haplotype
map of the human genome has greatly facilitated com-
prehensive genetic association studies of human disease
[48, 55, 103].
SNP associations are currently being detected at an
unprecedented pace for many neuropsychiatric disorders
[65, 66, 87, 103; see also Table 5). The chips allow the
determination of genotypes for the number of SNPs that
are detected with the respective oligonucleotides; cur-
rently, determination of 1 million SNP genotypes in every
individual tested is feasible; only very small amounts of
DNA are required. If 2,000 cases and 2,000 controls are
analyzed in an association study, a total of 2 9 2,000 9
1 million genotypes are generated. Both allele and geno-
type frequencies for every single SNP can be compared;
P values of 0.05 divided by 106 (simple Bonferroni cor-
rection for the 1 million tests), i.e., P values smaller than
0.00000005 (5 9 10-8), indicate genome-wide significant
differences between cases and controls for the respective
SNP. However, a Bonferroni correction is too conserva-
tive because many SNPs are in linkage disequilibrium
with other SNPs implying that the respective alleles are
not independent. Nevertheless, in light of the hypothe-
sized small effect sizes of variants underlying complex
disorders the necessity to analyze very large samples of
both cases and controls is readily evident. Thus, the
absence of significant findings in ADHD GWAS most
likely reflects the too low number of cases and controls or
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trios (index patient and both parents) in the currently
published studies (see [9]).
The future and a word of caution
What can realistically be expected for the future? Two
extreme scenarios appear possible: (1) only a limited
number of novel gene variants are unambiguously identi-
fied within the next 5 years. This finding would imply that
the effect sizes of most predisposing alleles are so small
that they cannot be picked up. The ultimate step would be
to re-sequence the whole genome (or at least all known
genes) in a substantial number of cases and controls in an
attempt to statistically identify those loci in which varia-
tions cluster in cases [105]. Genome-wide re-sequencing is
currently, however, not yet feasible in a large number of
individuals. Moreover, special statistical methodology for
this data is still in its infancy. The accumulating costs for
the search for alleles with very small effect sizes at some
time point will need to be put into perspective to the
expected outcome. (2) GWAS lead to the identification of
at least ten novel gene variants for each analyzed psychi-
atric disorder. These genetic results are robust, implying
that there is a consensus that indeed the respective genes
contribute to the etiology of the respective disorder;
(repeated) replications of each single finding are the pre-
requisite for the attainment of such a consensus. This
knowledge will allow us to identify (a) the molecular
genetic mechanisms relevant for psychiatric disorders (e.g.,
variation primarily within regulatory versus coding
regions), (b) novel systems and pathways relevant in spe-
cific disorders, which may or may not include pharmaco-
logical targets, (c) the extent of overlap in the genetic
predisposition to different psychiatric disorders (e.g.,
identification of genetic variation predisposing to both
ADHD and autism; see [133]), (d) gene–gene and gene-
environment interactions and (e) developmental relation-
ships between genotype and phenotype.
The crucial prerequisite for the use of sophisticated
molecular technology is that several large and well-char-
acterized samples of patients with a given disorder exist to
allow repeated confirmations of a single finding and sub-
sequent meta-analyses. By large, we imply that the
respective samples should encompass well over 1,000
cases and an equal number of controls, thus providing
sufficient power to detect alleles with a modest to weak
effect. Undoubtedly, the need to analyze large samples and
to confirm original findings will lead to extensive collab-
orations which need to also address ethnic aspects; the
contribution of single researchers and groups to novel
results will become small; thus, a total of 146 authors
contributed to a recent GWAS for BMI [175]. Family-
based association and linkage studies will also be helpful in
specific situations such as the involvement of imprinted
genes in the etiology of a given disorder.
As the field of molecular genetics of psychiatric disor-
ders advances, we as child and adolescent psychiatrists
need to stay at the forefront of these developments. To
achieve our goals we depend on an interdisciplinary
approach also encompassing molecular geneticists and
biologists, biostatisticians, and several other specialists.
We will profit by extensively integrating these disciplines
into our research; a fundamental issue is to establish a
sufficient amount of cross-talk to ensure that the full
potential of this interdisciplinary approach can bear full
profit. We as psychiatrists will also be responsible for the
integration of novel molecular findings into our clinical
routine. We need to be aware of ethical and societal
implications of molecular genetic findings. We need to
have training programs which provide us with the capa-
bility to grasp the molecular findings and to integrate them
into novel research (e.g., analysis of gene–environment
interactions) and even more important into our daily clin-
ical routine if the evidence is strong enough. If a suffi-
ciently large number of predisposing alleles for a given
disorder become known, genetic analyses will most likely
for the first time provide us with genetic markers useful for
diagnostic purposes, prediction of the clinical course of a
disorder and its treatment (personalized medicine). We will
learn that the elucidation of the molecular puzzle of psy-
chiatric disorders has the potential to alter our current
phenomenological basis for the definition of neuropsychi-
atric disorders.
Despite these exiting potential implications of the dis-
covery of predisposing alleles, we nevertheless should
remain critical. Due to the necessity to reach a diagnosis
via explicit diagnostic criteria, we as psychiatrists have
become extremely critical of our own research work; with
good reason we have come to expect a solid diagnostic
procedure based on standard criteria. We would recom-
mend that this critical approach is extended to the field of
psychiatric genetics, where at times novel results are either
extended beyond the evidence or are uncritically taken for
granted.
For example, in 1993, Brunner and co-workers [15, 16]
reported that a mutation in the MAO-A gene underlies a
phenotype characterized by ‘borderline mental retardation’
and ‘aggression’. This study is widely held to indicate that
human aggression can be caused by a mutation in a single
gene. However, the phenotype depicted in the respective
publications is anything but straight forward: the mutation
carriers were reported to have been involved in voyeurism,
exhibitionism, arson and/or rape. The affected males were
described as ‘…withdrawn and shy, being often without
friends. All have shown aggressive outbursts of some sort,
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usually with little or no provocation. A number of males
exhibit sexually aberrant behavior… Aggressive behavior
tended to cluster in periods of 1–3 days, during which the
affected male would sleep very little and would experience
frequent night terrors.’ No attempt was made to classify the
symptoms according to a psychiatric classification scheme.
The common trait appears to be ‘aggressive outbursts of
some sort’, which without further specification could well
apply to a substantial minority of the general population.
This criticism all the more applies because the investigators
deduced the presence of borderline mental retardation in
nine males of the pedigree from information compiled
30 years ago by an unaffected family member. The only
information provided for those mutation carriers whom the
investigators themselves were able to phenotypically assess
was as follows: ‘A typically affected male showed a full-
scale IQ of 85’. It was not specified how many of the males
were psychologically tested and what IQ test was used (for
a more detailed critical evaluation of the Brunner et al.
studies [15, 16], see [63], and the response of Brunner et al.
[14]). Conceivably, the MAOA mutation entails symptoms
compatible with the diagnosis of a personality disorder,
which, in turn, could be associated with aggressive
behavior in specific circumstances. In our opinion, there is
no reason for us to be lenient when molecular geneticists
uncover genetic variation underlying interindividual dif-
ferences in behavioral phenotypes, particularly if they are
as complex as aggression or intelligence. This is particu-
larly important because the media frequently simplify and
exploit such findings, thus conveying false or largely
imprecise information to the lay public.
The delineation of the ‘aggression gene’ (term used by
the media; see e.g., [156]) paved the way for another
sensational finding, which pertains to a genotype–envi-
ronment interaction, only few of which have been studied
in psychiatry. MAO-A alleles can be classified as leading to
low or high activity of its gene product; a study published
in Science in 2003 [21], which was purportedly indepen-
dently confirmed [44], showed that maltreated children
with a genotype conferring low levels of MAO-A were less
likely to develop conduct disorders.
Why should such an exciting finding be subjected to a
critical evaluation? Critical issues include (for a more
detailed and general discussion of gene 9 environment
interactions see also [174]): (1) solid molecular genetic
findings in complex disorders are as yet scarce. There is no
a priori evidence to indicate that a switch to gene–envi-
ronment interactions will make the elucidation of predis-
posing alleles easier. (2) The delineation of a single
specific hypothesis pertaining to a gene–environment
interaction implies that just this one out of very many
different possible ones is tested; both the gene (e.g., MAO-
A) and the environmental condition (e.g., maltreatment)
must be selected. If, however, different gene–environment
interactions are tested, the effects of multiple testing need
to be considered. (3) The quality of the underlying
hypothesis needs to be assessed. The investigation of
MAO-A in conduct disorders to a considerable extent rests
on the aforementioned study of Brunner et al. [15, 16],
which as delineated above was not satisfactory in defining
a psychiatric phenotype. (4) Confirmatory studies in gene–
environment analyses become almost impossible if the
original assessment procedure for the relevant environ-
mental factor is not employed in subsequent studies. Foley
et al. [44], who used different variables to construct a
maltreatment index than Caspi et al. [20], elegantly discuss
this problem by speculating that their own positive
molecular genetic results suggest that the measures used by
the two different groups are ‘intercorrelated and they may
indicate an overlapping set of environmental risks’. A
direct comparison of the variables assessed in the two
studies is not too convincing to make this circular rea-
soning plausible. To the contrary, it seems probable that the
two distinct sets of variables used to construct the mal-
treatment indices tap on different environmental and
genetic factors; the extent of overlapping is subject to
debate. (5) Finally, as Foley and co-workers [44] note,
most of the power to detect the interaction stemmed from
the extremes of the distribution. Only 15 and 5 subjects out
of a total of 514 were ranked to be in the second highest
and highest level of exposure to childhood adversity. The
genotypes of these 20 subjects in total accounted for the
significant effect of the genotype–environment interaction
and thus for the confirmation of the original Caspi et al.
[21] study.
In the context of such gene–environment interactions, a
recent meta-analysis deserves notice: despite previous
reports to the contrary, the serotonin transporter genotype
alone or in interaction with stressful life events was not
found to be associated with an elevated risk of depression
in men alone, women alone, or in both sexes combined; the
number of stressful life events was however associated
with depression [131].
There are no easy solutions to these problems. The
complexity of the issues at hand requires that psychiatrists
apply all their knowledge to adequately conduct genetic
studies and to assess novel genetic findings. We believe
that the elucidation of genes involved in psychiatric dis-
orders has a tremendous potential to advance our under-
standing of their aetiologies and to contribute to future
therapies. At the same time we need to remain humble in
light of the complexity inherent to genetic and environ-
mental factors in psychiatric disorders.
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